Overview

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

Status:
Completed
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
The main objective of the study is to assess preferences of Non Valvular Atrial Fibrillation (NVAF) patients towards different options of an anticoagulation treatment. Patient preferences for anticoagulant treatment attributes (convenience attributes only), based on a Discrete Choice Experiment(DCE) interview will be elicited and the impact of switching from Vitamin K Antagonist(VKA) to Xarelto® on Atrial Fibrilation(AF) patient treatment satisfaction will be documented, measured by score differences of the Anti-Clot Treatment Scale (ACTS) score in patients switching from VKA to Rivaroxaban.
Details
Lead Sponsor:
Bayer
Collaborator:
Janssen Research & Development, LLC
Treatments:
Rivaroxaban